Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron

Share Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on Facebook Share Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on Twitter Share Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on Linkedin Email Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron link

The Competition and Markets Authority's (CMA) purpose is to help people, businesses and the UK economy by protecting competition and tackling unfair behaviour.

About this consultation

The CMA is consulting on commitments offered by Vifor Pharma in relation to the CMA’s investigation into Vifor Pharma’s conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998. The CMA’s investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor’s intravenous iron treatment, Monofer, supplied by Pharmacosmos, as compared to Vifor Pharma’s own product, Ferinject.

To address the competition concerns the CMA identified during the course of its investigation, Vifor Pharma has offered commitments to:

  • make an ex-gratia payment of £23 million to the NHS
  • correct any potentially misleading communications disseminated by Vifor Pharma regarding the safety of Monofer and Ferinject, via a multi-channel communications campaign to healthcare professionals
  • introduce several compliance measures to prevent the future dissemination of potentially misleading communications regarding the safety of Monofer and Ferinject to healthcare professionals

This consultation closes at 5pm on 17 January 2025.

We want to hear from you

The CMA provisionally considers that the proposed commitments address the competition concerns identified by the CMA for the reasons set out in the Notice of Intention to Accept Commitments. Therefore, subject to consultation responses, the CMA proposes to accept the proposed commitments.

The CMA is now inviting views from stakeholders on the proposed commitments.

Responding to our consultation

Send your responses by email to: 51377-consultation@cma.gov.uk with the subject line ‘Case 51377 – Response to Vifor Proposed Commitments’.

The CMA does not intend to publish any responses, however, the information contained in the responses may be used or summarised on an anonymous basis. If your response contains any information that you regard as sensitive and that you would not wish to be published, please identify the information and explain why you regard it as sensitive.

Your personal data

Any personal data you provide to us through CMA Connect (such as your name and contact details) will be handled in accordance with our obligations under the UK General Data Protection Regulation and the Data Protection Act 2018.

Our personal information charter set out the standards you can expect from us when we collect, use or share personal data and provides details of your rights in relation to that personal data and how to contact us.

The Competition and Markets Authority's (CMA) purpose is to help people, businesses and the UK economy by protecting competition and tackling unfair behaviour.

About this consultation

The CMA is consulting on commitments offered by Vifor Pharma in relation to the CMA’s investigation into Vifor Pharma’s conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998. The CMA’s investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor’s intravenous iron treatment, Monofer, supplied by Pharmacosmos, as compared to Vifor Pharma’s own product, Ferinject.

To address the competition concerns the CMA identified during the course of its investigation, Vifor Pharma has offered commitments to:

  • make an ex-gratia payment of £23 million to the NHS
  • correct any potentially misleading communications disseminated by Vifor Pharma regarding the safety of Monofer and Ferinject, via a multi-channel communications campaign to healthcare professionals
  • introduce several compliance measures to prevent the future dissemination of potentially misleading communications regarding the safety of Monofer and Ferinject to healthcare professionals

This consultation closes at 5pm on 17 January 2025.

We want to hear from you

The CMA provisionally considers that the proposed commitments address the competition concerns identified by the CMA for the reasons set out in the Notice of Intention to Accept Commitments. Therefore, subject to consultation responses, the CMA proposes to accept the proposed commitments.

The CMA is now inviting views from stakeholders on the proposed commitments.

Responding to our consultation

Send your responses by email to: 51377-consultation@cma.gov.uk with the subject line ‘Case 51377 – Response to Vifor Proposed Commitments’.

The CMA does not intend to publish any responses, however, the information contained in the responses may be used or summarised on an anonymous basis. If your response contains any information that you regard as sensitive and that you would not wish to be published, please identify the information and explain why you regard it as sensitive.

Your personal data

Any personal data you provide to us through CMA Connect (such as your name and contact details) will be handled in accordance with our obligations under the UK General Data Protection Regulation and the Data Protection Act 2018.

Our personal information charter set out the standards you can expect from us when we collect, use or share personal data and provides details of your rights in relation to that personal data and how to contact us.

Page published: 10 Dec 2024, 07:01 AM